

Orthokeratology and Myopia Management - where are we today?







Heterogeneous Anti-Myopia Efficacy of OrthoK									
Study or Subgroup	Orthokeratology Mean SD Total			Control Maan SD Total Weight			Weight	Mean Difference	Mean Difference
Oharry 20042	0.40	0.04	10101	0.54	0.00	10101	C ON	0.001.0.50.0.401	14, Raildolli, 39/6 01
Chan 2013	0.19	0.21	26	0.64	0.32	22	0.9%	-0.32 [-0.52, -0.12]	
Che 2005	0.31	0.27	35	0.64	0.31	25	16 7%	-0.35 [-0.48, -0.17]	
Cho 2012	0.26	0.24	37	0.63	0.26	41	21.8%	-0.27 [-0.38 -0.16]	
Kakita 2011	0.30	0.27	42	0.61	0.24	50	24.2%	-0.22 [-0.33 -0.11]	
Santodomingo-Rubido 2012	0.47	0.18	29	0.69	0.32	24	13.0%	-0.22 [-0.36 -0.08]	
Walline 2009	0.97	0.10	28	0.57	0.51	28	6.3%	-0.32 [-0.53 -0.11]	
Total (95% CI) Heterogenety Tau" = 0.00; Ch" = 2.37, df = 6 (P = 0.88); P = 0% Test for overall effect: Z = 9.90 (P < 0.00001) Favours orthokeratology Favours control									
Reasonable consistency but significant individual variability!									
erkelev Optometry									

#### Source of Variance of Effect Size

#### Issues in defining anti-myopia efficacy

- Absolute vs. relative efficacy (nonlinear for baseline AL & stage of myopia)
- Confounding effects from physiological axial growth
- Complex genetic vs. environmental contributions to myopia etiology
- Stronger genetic predisposition, less responsive to intervention
- OrthoK-specific challenges
  - Exact mechanisms unclear
- Treatment lacks specificity (i.e. treatment dosage difficult to measure)





Orthokeratology and Myopia Management - where are we today?















### Orthokeratology and Myopia Management - where are we today?

Baseline Myopia & Controlling Efficacy of OrthoK -Confounding from Age The earlier the onset, the more genetic predisposition, less responsive to interventions





#### Summary

Myopia-inhibiting effect subject to significant variability

- definition of "anti-myopia" efficacy needs further improvement - AL elongation not only myopia progression- but age-dependent
- AL elongation not only myopia progression- 
  various response to treatment
- Myopia-controlling dosage induced by OrthoK
- comes from both central non-uniform flattening & paracentral steepening
- lacks design-specificity, hence post-treatment corneal shape as exposure
- Anti-myopia efficacy independent of baseline myopia

- earliest intervention possible to minimize risk of excessive scleral stretching

Berkeley Optometry









Orthokeratology and Myopia Management - where are we today?











Orthokeratology and Myopia Management - where are we today?

